alirocumab
regeneron,sanofi
['alirocumab', 'odyssey', 'cardio']
results from odyssey outcomes trial on alirocumab: transient very low ldl-c levels improve long-term cv outcomes: just presented #acc.23 #ehj #statin #pcsk9 #inhibitor #cardiotwitter 
Official twitter account of the European Heart Journal Editor-in-Chief. Tweets by Prof. Filippo Crea and his team. #EHJ.